Loading...
•
Jun 30, 2023
10X Genomics Q2 2023 Earnings Report
Reported a 28% increase in revenue compared to the corresponding period of 2022, driven by strong momentum in Xenium and double-digit growth of Chromium single cell consumables.
Key Takeaways
10x Genomics reported a strong second quarter with revenue of $146.8 million, a 28% increase year-over-year. The company is raising its full year 2023 revenue guidance to a range of $600 million to $620 million.
Revenue was $146.8 million for the second quarter, representing a 28% increase over the corresponding period of 2022.
Accelerated Xenium's momentum with strong shipments, multiple new curated and customizable gene panels and a major update of its onboard software to deliver even higher levels of performance.
Launched the Visium CytAssist Gene and Protein Expression assay, combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection.
Delivered double-digit growth of Chromium single cell consumables and increased Chromium X Series placements year over year, led by strong performance in the Americas and EMEA.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $600 million to $620 million, representing 16% to 20% growth over full year 2022. This compares to its previous revenue guidance of $590 million to $610 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...